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Background: Octopamine receptors (OARs) perform key functions in the biological pathways of primarily
invertebrates, making this class of G-protein coupled receptors (GPCRs) a potentially good target for insecticides.
However, the lack of structural and experimental data for this insect-essential GPCR family has promoted the
development of homology models that are good representations of their biological equivalents for in silico
screening of small molecules.
Methods: Two Anopheles gambiae OARs were cloned, analysed and functionally characterized using a heterologous
cell reporter system. Four antagonist- and four agonist-binding homology models were generated and virtually
screened by docking against compounds obtained from the ZINC database. Resulting compounds from the virtual
screen were tested experimentally using an in vitro reporter assay and in a mosquito larvicide bioassay.
Results: Six An. gambiae OAR/tyramine receptor genes were identified. Phylogenetic analysis revealed that the OAR
(AGAP000045) that encodes two open reading frames is an α-adrenergic-like receptor. Both splice variants signal
through cAMP and calcium. Mutagenesis analysis revealed that D100 in the TM3 region and S206 and S210 in the
TM5 region are important to the activation of the GPCR. Some 2,150 compounds from the virtual screen were
structurally analysed and 70 compounds were experimentally tested against AgOAR45B expressed in the
GloResponse™CRE-luc2P HEK293 reporter cell line, revealing 21 antagonists, 17 weak antagonists, 2 agonists,
and 5 weak agonists.
Conclusion: Reported here is the functional characterization of two An. gambiae OARs and the discovery of new
OAR agonists and antagonists based on virtual screening and molecular dynamics simulations. Four compounds
were identified that had activity in a mosquito larva bioassay, three of which are imidazole derivatives. This combined
computational and experimental approach is appropriate for the discovery of new and effective insecticides.
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Despite decades of research and multiple initiatives, vector-
transmitted diseases remain a major public health threat
throughout the world. Blood-feeding insects transmit some
of the most debilitating infections known to mankind,
including malaria, lymphatic filariasis, yellow fever, and
leishmaniasis. Malaria is the most deadly vector-borne
disease in the world, threatening about 40% of the world’s
population and causing nearly one million deaths, primarily
in African children [1]. Anopheline mosquitoes are the pri-
mary vectors of Plasmodium parasites, the causative agents
of malarial disease to humans. Although the implementa-
tion of artemisinin-based combination therapies in the
mid-1990s helped to reduce the global mortality and mor-
bidity due to malaria, vector control has been the corner-
stone of malaria control programs, primarily through the
use of insecticide-treated bed nets and to a lesser extent,
indoor residual spraying. The recent emergence of artemisi-
nin resistance in Plasmodium falciparum [2] underscores
the role of vector control for reducing the devastation of
malaria world-wide. Unfortunately, insecticide resistance is
increasing globally, requiring development of more effective
insecticides [3].
Octopamine and tyramine are related biogenic mono-
amines that act as neurohormones, neuromodulators and
neurotransmitters in invertebrates [4,5], performing essen-
tial functions and modulating many crucial physiological
processes. These processes include learning and memory,
locomotion, feeding behaviours, the pheromone response,
and cardiac function. In addition, octopamine plays this
physiological role in invertebrates only [4,5]. These rea-
sons make octopamine receptors (OARs) excellent targets
for developing new and safer insecticides.
Formamides such as dimethylchlordimeform and amitraz
mimic octopamine and provide broad-spectrum insecticidal
activity [6]. These insecticides have been used in veterinary
practice to control ticks for nearly 40 years, however the
quest for novel control compounds that target OARs has
been relatively ineffective. However, recent technological
developments in screening protocols, however, may reverse
this trend [4].
OARs are G-protein coupled receptors (GPCRs), a family
of seven transmembrane (TM) receptors that are involved
in many diseases and are the target of approximately 30%
of all modern medicinal drugs [7,8]. GPCRs are called such
because they interact with G-protein trimeric complexes,
the three main types being Gαs, Gαi, and Gαq.
Few GPCR crystal structures have been elucidated due
to the complexity of these proteins as well as their location
in lipid membranes. While the limited crystal structures
that have been solved generally have low sequence identity
(for example, the sequence identity of the β2-adrenergic
receptor and rhodopsin is below 20%), the 3D structures of
their TM regions are found to be very similar. Largestructural differences are generally found in the loop
regions, where location and secondary structure between
the receptors can deviate [9]. Realizing this characteristic,
it is hypothesized that 3D molecular modelling using an
existing GPCR model as a template, and performing a
simulation on the resulting model, will fix major variations
from the existing model and prepare a novel GPCR for
virtual screening.
GPCRs are activated via agonists docking to the interior
of the receptor near the extracellular side. To date, three
residues have been found to be important for the activa-
tion of most GPCRs. These are an aspartic acid in the
third TM region (TM3) and two of three closely grouped
serine residues found in TM5. The endogenous biogenic
amine agonist appears to hydrogen bond via its amine
group and its hydroxyl groups to the aspartic acid and
serines of the GPCR, respectively [10-12].
Studies have been conducted studying OARs of other
insects, including the honey bee [13], silkworm [14], cock-
roach [15], and fruit fly [16,17]. These have mostly been
molecular and functional characterizations of the receptor,
though many studies have yielded the effects of common
GPCR agonists and antagonists on their respective OARs.
Here, an OAR from Anopheles gambiae mosquitoes was
characterized and novel agonists and antagonists were
discovered through molecular dynamics (MD) simulations




Anopheles gambiae (strain PEST) mosquitoes were raised
and maintained in an environmental chamber at 26°C,
85% relative humidity, with a 16-hour light, eight-hour
dark cycle including a one-hour dusk/dawn period [18].
Larvae were fed daily a 2:1 mixture of fish pellets:
brewer’s yeast, that had been finely ground [19]. DL-
octopamine, tyramine, dopamine, naphazoline, clonidine,
serotonin, chlorpromazine, cyproheptadine, promethazine,
all hydrochloride salts, and tolazoline a benzylimidazoline
salt, were obtained from Sigma-Aldrich. Metoclopramide
hydrochloride was obtained from MP Biomedical. Com-
pounds identified in the virtual screen were purchased
from Princeton BioMedical, ChemDiv, Chembridge and
Enamine and tested in vitro against AgOAR45B expressed
in the GloResponse™CRE-luc2P HEK293 reporter cell line
and in larval bioassays.
Expression analysis of AgOAR45A and AgOAR45B
Total RNA was isolated from five different An. gambiae
immature stages (L1-P), adult females and males, adult
female heads only, and adult female abdomen/thorax using
the RNeasy Mini Kit (Qiagen). The DNase (Fermentas)-
treated RNA was used to generate cDNA using Superscript
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turer’s recommendations. Quantitative PCR (qPCR) was
performed using SYBRGreen (ABI), an ABI 7900 RT-PCR
system and 200 ng of cDNA per sample, a final concentra-
tion of 0.15M of each primer, and an annealing temperature
of 60°C. Primer sets used for expression analysis were:
Ag10592 forward- CACCATCGAACACAAAGTTGACA
CTT; Ag10592 reverse- CGAACGTAACGTCACGGCCA;
Ag45A&B forward- GGGTACGTCGTCTACTCAGCCC
TC; Ag45A reverse- TGTATCCGCAGCGTTAGCCGAT
TG; Ag45B reverse- CGAGATTGTTCTTGCCACCTTTG
GTG. The 40S Ribosomal protein subunit 7 (AGAP01592)
was used as an internal control. Reactions for each gene and
for the control used were carried out in triplicate. Relative
expression levels of each gene was determined by the ΔΔCT
method, where relative expression is expressed as a fold dif-
ference relative to whole females and expressed as 2- ΔΔCT.
The following formula was used: ΔΔCT = ΔCT(stage or
condition) − ΔCT(Females) and ΔCT = CT (gene of interest) −
CT (40S RNA).
Heterologous expression of AgOAR45B octopamine
receptor
Total RNA was isolated from heads of three-day old adult
females using RNeasy Mini Kit (Qiagen). cDNA was
synthesized using SuperScript III (Invitrogen), and used as
a template for PCR amplification of the AgOAR45A and
AgOAR45B genes. Insertion of the coding sequences into
the SgfI and PmeI sites of the pF9a CMV hRluc-neo
vector (Promega) was performed by digestion of a frag-




ACCACCGACGA. Primers were constructed based on
the annotated sequence of the AGAP000045 gene
(VectorBase, Protein ID: AGAP000045-PA and -PB [20].
GloResponse™CRE-luc2P HEK293 reporter cell line
(Promega) were maintained as adherent culture at 37°C,
5% CO2 in DMEM (Invitrogen) supplemented with 10%
fetal calf serum (Atlanta), and 50 mg/ml hygromycin B.
Transfection of cells was carried out using the Amaxa
Nucleofector kit per the manufacturer’s instructions. Con-
trol transfections were performed using a pF9A plasmid
with the barnase (Bacterial Ribonuclease) gene removed
as suggested by the manufacturer (Promega). Stable lines
were created by applying 400 mg/ml G418 for three
weeks. Stable clones of AgOAR45B expressing HEK293
reporter cells were created through two rounds of limiting
dilution cloning.
cAMP assay
Intracellular cAMP increase was monitored through a
CRE-luc reporter construct in HEK293 cells (Promega).Stable cell lines were plated at a density of 4×104 cells
per well in white 96-well assay plates (Corning, Cat.
#3917). Cells were immediately treated with the various
compounds, and returned to the incubator for four
hours before being assayed. cAMP was quantified
through luciferase production using the Dual-Glo lucif-
erase assay kit (Promega) following the manufacturer’s
instructions. Luciferase units were normalized to the cell
number using the internal Rluc construct in the pF9A
expression plasmid.
Intracellular Ca++ assay
Stable cell lines expressing AgOAR45A or AgOAR45B
were plated in black well, clear bottom, 96-well assay
plates (Greiner Bio-One, Cat. #655090) at 4×104 cells per
well. Cells were allowed to grow overnight before being
assayed. Cells were preloaded with Fluo-4 NW (Molecular
Devices), and carried out per the manufacturer’s instruc-
tions. Fluorescence was monitored before and after
addition of compounds using the Flexstation3 (Molecular
Devices), at two-second intervals for 120 seconds.
Site-directed mutagenesis of AgOAR45B
The AgOAR45B gene was subcloned into a TA vector
(Invitrogen), according to the manufacturer’s instructions.
Site-directed mutagenesis of AgOAR45B was carried out
using Quick Change Lightning Kit (Agilent). Primers
(IDT) were designed to introduce single amino acid
changes (see Additional file 1). Double mutants were cre-
ated through two rounds of mutagenesis. Mutations were
confirmed through automated sequencing (ND Genomics
Core Facility). Mutant genes were then excised and moved
to the pF9A expression vector as described above.
Membrane preparation and radioligand binding assay
Cells in T75 flasks were washed with 10 ml of PBS,
removed by scraping, centrifuged at 500 g, and then resus-
pended in 5 ml of lysis buffer, 50 mM Tris-Cl pH 7.4.
Cells were incubated on ice for 10 min and homogenized
with a Dounce homogenizer with 30 strokes. The hom-
ogenate and 5 ml wash with lysis buffer were then centri-
fuged at 23,000 g for 30 min at 4°C to pellet crude
membranes. The resulting pellet was re-suspended in 50
mM Tris-Cl pH 7.4, 5 mM MgCl2, 0.5 mM EDTA pH 7.4
and quantified by micro BCA assay (Thermo).
Radioligand binding assays were carried out using
3H-Yohimbine to determine binding affinity of the oc-
topamine receptor with different compounds. Isolated
membranes, 30 μg per well, were incubated in the pres-
ence of 16 nM 3H-Yohimbine (American Radiolabeled
Chemicals) in binding buffer, and various concentrations
of compounds. The final reaction volume was 125 ml per
well in a 96-well assay plate. One-hundred mM cloni-
dine was used to determine non-specific binding in each
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collected and washed on filter mats, pretreated with 0.3%
polyethylenimine (Sigma) using a Brandel 96-well harvester
and counted in a Perkin Elmer Microbeta counter.
Larval bioassay
Dose response curves were made to determine the LD50
for some compounds against three-day old Aedes aegypti
larvae. Ten larvae were put in each well of a 12-well
plate, with each well containing a different concentration
of compound in water. Three replicate wells were made
for each experiment and the curves performed three
separate times. Control wells were included in each
experiment, which contained only DMSO in water.
Plates were incubated 24 hours in standard insectary
conditions. Mortality was determined after 24 hours.
Project workflow
A computational-experimental workflow (see Additional
file 2), similar to the computational approach described
by Yarnitzky et al. [21] was utilized. The method was as
follows: 1) homology models, both inactive (antagonist-
based) and active (agonist-based) conformations, were
created using the fragment-based method I-TASSER
(Iterative Threading Assembly Refinement) [22-24] as
well as surrounded by lipids, water, and ions using visual
molecular dynamics (VMD) [25]; 2) a preliminary virtual
screen with one of two compound test sets (composed
of either GPCR agonists or antagonists whose activity on
AgOAR45B was experimentally determined using an
AgOAR45B reporter assay) was performed and a set of
top-ranked positions of the most were chosen and used in
MD simulations with the proper active (agonist-binding)
and inactive (antagonist-binding) protein conformations;
3) MD simulations were performed until stable ligand
positions were obtained, then an additional virtual screen
with the test set was performed on each resulting protein
conformation and the results were analysed manually.
Step 3 was repeated until the ligand positions were stabi-
lized in the protein even after ten additional nanoseconds
(ns) of simulation; 4) final conformations were then used
to build grids which were subjected to virtual screening
using the ZINC library; and, 5) the resulting compounds
were analysed and compounds with differing structural
characteristics were purchased and experimentally tested
in vitro.
Homology modelling
Both initial inactive (antagonist-based) and active (agonist-
based) conformations of AgOAR45B were generated using
the I-TASSER online server [26]. For the inactive con-
formation, a structure was obtained that was built based
on many GPCR antagonist-bound and inverse agonist-
bound conformations, primarily a crystal structure of β2-adrenergic receptor with partial inverse agonist carazolol
bound [PDB:2RH1]. For the active conformation, a struc-
ture was obtained that was built based on the crystal struc-
ture of the β2-adrenergic receptor-Gαs protein complex
with high affinity agonist BI-167107 bound [PDB:3SN6].
Both conformations were obtained using standard I-
TASSER settings. In the case of the active conformation of
AgOAR45B, 3SN6 (chain R) was used as a template to gen-
erate the model. Root-mean-square deviations (RMSDs), as
a measure for protein stability, were calculated using the
VMD 1.9 RMSD Trajectory Tool [25]. AgOAR45B has a
24% sequence identity (35% similarity) to the β2-adrenergic
receptor (see Additional file 3). The active site residues
were determined from analyzing the inactive and active β2-
adrenergic receptor’s crystal structures and observing resi-
dues that interacted or had the potential to interact with
the crystal structures’ bound ligands [27,28]. The active site
sequence identity is much higher at 67% (73% similarity).
Molecular dynamics
Using VMD 1.9, each virtual representation of the protein
was first embedded in a large 1-palmitoyl-2-oleoylpho-
sphatidylcholine (POPC) lipid bilayer, removing any lipid
that overlapped with the protein. The virtual protein-
membrane system was then solvated with TIP3P water
molecules, and neutralized by virtually adding KCl up to
400 mM. Initially, CHARMM 27 parameters [29] were
assigned to all molecules using VMD 1.9 to enable the
addition of the lipid bilayer, water and ions. However, once
each virtual system (both active and inactive conform-
ation) was prepared and its respective ligand (octopamine
for the active conformation and promethazine for the
inactive conformation) was ready to be added, AMBER
gaff and ff03.r1 parameters were assigned to the ligand
and the rest of the molecules, respectively, using Amber
11 tleap [30-32]. The AMBER force field was chosen as it
allows the generation of parameters for the ligand using
the antechamber module [33]. A disulphide bridge was
added between the residues of Cys93 and Cys194, as this
bridge also existed in the template PDBs.
Each complete virtual system consisted of the respective
conformation of AgOAR45B embedded to a large POPC
bilayer with 168 lipid molecules. In each virtual system, all
residues were at the normal protonation state for physio-
logical pH. In addition, the antagonist- bound system con-
tained 171 potassium ions, 204 chloride ions, and 22,525
water molecules for a total of 99,706 atoms (measured
95×96×128 Å), while the agonist-bound system contained
172 potassium ions, 205 chloride ions, and 22,654 water
molecules for a total of 100,077 atoms (measured
101×92×127 Å). Before MD simulations the systems were
equilibrated using 120 CPU cores as follows: 1) MD of
lipid tails for 500 picoseconds (ps) [time step = 2 femto-
seconds (fs)] with protein, ligand, lipid head groups, water,
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ions for 500 ps (time step = 2fs) with harmonic constraints
on the protein and ligand; 3) equilibration of the entire
system for 500 ps (time step = 2fs) with no molecular con-
straints. After equilibration, 20–30 ns of MD simulation
were performed using 504 CPU cores in two to three 10
ns increments, with time step = 2fs and trajectory data
being collected every 200 ps. The equilibration and simu-
lation steps were run using NAMD 2.8 [34] on the high-
performance computing cluster Kraken [35].
Virtual screen preparation
All virtual screening jobs were run on their respective
‘protein only’ homology models (i.e., containing no lipids,
waters or ions). The proteins were prepared by first run-
ning the Protein Preparation Wizard workflow [36,37],
and then grids were generated using Glide’s Receptor Grid
Generation application, each found in Schrodinger Suite
2011’s Maestro [38]. To obtain initial ligand poses used in
grid generation, each of the conformations were first
overlapped in PyMOL [39] with the top templates used by
I-TASSER for their creation (2RH1 for the inactive con-
formation and 3SN6 for the active conformation) and the
positions of the ligands found in each of the templates were
first saved as a PDB file, then added using Schrodinger
Suite 2011’s Maestro to their respective AgOAR45B con-
formation (2RH1 partial inverse agonist CAU was used
for the inactive conformation and 3SN6 agonist 30G was
used for the active conformation) to denote the active site
of the protein. The ligand added to each of the homology
models was used as the centroid of the grid, determining
the area in which the libraries of compounds should be
docked. No constraints were used.
Virtual screening with known GPCR ligands
The inactive and active conformations of AgOAR45B with
the added ligands were used to build the grids, which were
then run in a virtual screen using Schrodinger’s Glide
software [40-43] against known GPCR antagonists and ag-
onists, respectively. The original compound structures
used in the two test sets were downloaded from the NIH’s
PubChem website. One of the test sets contains known
GPCR agonists: synephrine, cinnamic acid, clonidine,
demethylchlordimeform, dopamine, eugenol, histamine,
naphazoline, norepinephrine, octopamine, phentolamine,
serotonin, tolazoline, transanethole, and tyramine. The
other containing known GPCR antagonists: rauwolscine,
demethylchlodimeform, 8-hydroxymianserin, amitriptyline,
antazoline, chlorpromazine, cyproheptadine, desipramine,
desmethylmianserin, dihydroergotamine, gramine, imipra-
mine, maroxepin, metoclopramide, mianserin, phentola-
mine, prazosin, promethazine, propranolol, triprolidine,
and yohimbine. Each of the test sets was then prepared
using Schrodinger Maestro’s LigPrep [44] to generatedifferent potential protonation states at pH range 7–8,
tautomers and ring conformations. After each of the test
sets was docked to its respective AgOAR45B conformation,
top pose positions for the antagonist promethazine and the
agonist octopamine were saved and later added to the
inactive (antagonist-bound) and active (agonist-bound)
conformations, respectively. These protein conformations
with docked ligands were then used as the starting position
for the MD simulations.
Virtual screening with ZINC library
The library used in the docking contained drug-like com-
pounds from the ZINC online database [45]. Compounds
were prepared using Schrodinger Maestro’s LigPrep to
generate different potential protonation states at pH range
5–9, tautomers and ring conformations. The final library
contained approximately 12 million compounds. It was
split into five sublibraries (∼2.4 million compounds per
sublibrary) for the first run of high-throughput virtual
screening.
The library was screened against five grids of AgOAR45B
(two from the antagonist-bound conformations and three
from the agonist-bound conformations), built from the re-
ceptor positions after 20 ns of MD simulation each. Virtual
screening using the ZINC library was performed using
Schrodinger’s Glide software in three steps: 1) each of the
five sublibraries was filtered using high-throughput virtual
screening and the top 30,000 compounds in each sublibrary
were saved and recombined making a library containing
150,000 compounds; 2) this new library was then filtered
further using standard precision virtual screening and the
top 15,000 compounds were saved; and, 3) this new library
was then filtered one more time using extra precision
virtual screening and the top 1,500 compounds were saved
and analysed, considering the score, the relevant interac-
tions in the active site pocket and diversity in the sampling
for further testing.
Results
Molecular characterization of Anopheles gambiae
octopamine receptors
Anopheles gambiae OAR and the closely related tyramine
receptor (TyrR) genes were identified by homology search-
ing utilizing an OAR sequence (DmOamb) from Drosophila
melanogaster. Seven possible An. gambiae OAR/TyrR genes
were identified in VectorBase, AGAP000045, AGAP002519,
AGAP002888, AGAP002886, AGAP004034, AGAP013324,
and AGAP011698. One locus, AGAP011698, contained
only approximately one-half of the predicted coding se-
quence of DmOamb and, although likely encoding an OAR
or TyrR, was eliminated from further analysis. The closest
homologue to DmOamb was AGAP000045. Similar to the
DmOamb locus that encodes for two alternatively spliced
genes, DmOamb-D and DmOamb-B, the AGAP000045
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0045_OARA (AgOAR45A) of 1,779 bp and AGAP00
0045_OARB (AgOAR45B) of 1,773 bp, that encode putative
proteins consisting of 592 and 590 amino acids, respectively.
The splice variants have a deduced amino acid identity
of 56.1%, with the first three exons being identical and
the fourth and largest (1,046 bp for AgOAR45A and
1,040 bp for AgOAR45B) exons being alternatively
spliced (see Additional file 4A and B). The hydropathy
plot of both AgOAR45A and AgOAR45B revealed seven
hydrophobic domains, indicative of seven transmem-
brane-spanning regions typical of GPCRs (see Additional
file 4C). In addition, both predicted proteins contain the
GPCR characteristic aspartic acid (D) in TM3 and two
serine (S) residues in TM5.
Phylogenetic analysis
A phylogenetic tree was constructed using the ClustalX
2.1 and the neighbour joining method of 21 OARs and
TyrRs from An. gambiae, Ae. aegypti, Bombyx mori, Culex
quinquefasciatus, and D. melanogaster. The AGAP000045
predicted proteins group with the α-adrenergic-like recep-
tors, such as DmOamb (Figure 1), exhibiting a 34.9-37.5%
deduced amino acid identity similarity with the DmOamb
splice variants, a 20.7-21% similarity to DmOct-TyrR, a
10.8-18.2% similarity with the Drosophila β-adrenergic-
like receptors, and a 19.5-21.7% similarity to the Drosoph-
ila TyrR. AGAP002886 and AGAP002888 likely encode
for β-adrenergic-like receptors, AGAP002519 an OAR/
TyrR and AGAP004034 and AGAO013324 each a TyrR
(Figure 1).
Expression of AgOAR45B
Quantitative PCR was performed to assess the expres-
sion pattern of AgOAR45A and AgOAR45B at different
developmental stages and tissues of An. gambiae mos-
quitoes. Both genes were expressed in all life stages, with
the lowest expression being in the larval stages. Import-
antly, both AgOAR45A and AgOAR45B were expressed
in female heads (Figure 2).
Functional characterization of AgOAR45A and AgOAR45B
To functionally characterize AgOAR45A and AgOAR45B,
cDNAs of both proteins were separately cloned and stably
expressed into the GloResponse™CRE-luc2P HEK293
reporter cell line. Compared to the reported sequence
in VectorBase, the cloned AgOAR45A gene contained
five silent mutations and a 6-bp deletion resulting in
two fewer glutamines (Q426 and Q427) in a glutamine
repeat region. The cloned AgOAR45B gene differed
from the VectorBase sequence with two silent single
nucleotide polymorphisms (SNPs), two SNPs resulting
in a valine (V) at position 45 instead of an alanine (A)
and a switch from an arginine (R) at position 403 to aglutamine (Q), a 3-bp deletion resulting in the lack of
one histidine in a histidine repeat region and an inser-
tion of a valine (V) at the end of the sequence, due to
the cloning design.
Both genes signaled through cAMP (Gαs) and exhib-
ited typical OAR pharmacology [4], responding to oc-
topamine and other known octopamine receptor
agonists (clonidine, naphazoline, and phentolamine)
(Figure 3A) in the nM range and not to other biogenic
amines (dopamine and serotonin) (Table 1). As is typical
for OARs, both genes exhibited a dampened response to
tyramine (Figure 3A). The best agonists were clonidine
and naphazoline, inducing a response in the pM range
(Table 1), consistent with both receptors being α2-adren-
ergic receptor homologues [4]. The receptor responses
to octopamine were also inhibited by synthetic antago-
nists of OARs (chlorpromazine, cyproheptadine, meta-
clopramide, and promethazine) (Figure 3B and Table 1),
further indicating that both AgOAR45A and AgOAR45B
are functional OARs [4].
To examine the ability of AgOAR45A and AgOAR45B
to signal through Gαi, cAMP activity was assessed in the
presence of forskolin in response to octopamine and
naphazoline (agonists of OARs) and inhibitory activity
was not detected for either receptor. To monitor Ca2+
signals (Gαq signaling), HEK293 reporter cells stably ex-
pressing either AgOAR45A or AgOAR45B were pre-
loaded with the calcium sensitive dye Fluo-4 before
stimulation with octopamine. Both receptors also signal
through Gαq (see Additional file 5).
Discovery of five potential binding modes of AgOAR45B
As no functional differences between AgOAR45A and
A5OAR45B were detected, in silico characterization and
screening was performed with only AgOAR45B. Hom-
ology models of AgOAR45B were generated for both the
inactive (antagonist-bound) and active (agonist-bound)
conformations. As expected, the largest differences be-
tween the inactive and active conformations were the
intracellular and extracellular loops as well as both C
and N-termini, including the beginning of the TM1 re-
gion. In general, differences in the TM regions of the
two conformations were relatively small (see Additional
file 6). The models were refined by MD simulations with
the most active agonist (octopamine) and antagonist
(promethazine) of the test set for the active and inactive
conformations, respectively. For each of the four starting
positions, MD was run using two different seeds, resulting
in eight simulations total. For the inactive conformation,
promethazine bound in two different conformations to
D100 (Figure 4A and B). Similarly, three different binding
modes were found for octopamine after 20 ns MD sim-
ulation (Figure 4C-E). Three very different ligand positions























































Figure 1 Phylogenetic relationship of Anopheles gambiae AgOAR45A and AgOAR45B with other octopamine (OAR) and tyramine
(TyrR) insect receptors. Sequences from An. gambiae (AGAP000045, AGAP002519, AGAP002888, AGAP002886, AGAP004034, AGAP013324; Ae.
aegypti (AAEL004398, AAEL004396, AAEL006844, AAEL014224, AAEL016990, AAEL005952, AAEL005945), and Cu. quinquefasciatus (CPIJ019015) were
downloaded from VectorBase. Sequences from D. melanogaster [DmTyrRII (CG16766), DmTyrR (CG7431), DmOct-TyrR (CG7485), DmOamb-B
(CG3856-RB), DmOamb-D (CG3856-RD), DmOAbeta1 (CG6919), DmOAbeta3 (CG42244) and DmOAbeta2 (CG33976)] were downloaded from
FlyBase. Additional sequences, from Bombyx mori [BmOA1 (NP_001091748.1)], Apis mellifera [AmOA1 (NP_001011565.1)], and Tribolium [TcOAR1
(DAA64496.1)] were downloaded from GenBank. The alignment was performed on complete amino acid sequences and calculated using the
ClustalX 2.1 [49]. The tree was constructed using ClustalX 2.1, and the neighbor-joining algorithm with a bootstrap value of 1,000. Numbers on
branches are the percentage of bootstrap support for each branch node, only those above 50% are represented on the trees. The scale represents
the rate of amino acid substitution per site. AgOAR45A and Ag OAR45B are in bold.
Kastner et al. Malaria Journal 2014, 13:434 Page 7 of 14
http://www.malariajournal.com/content/13/1/434conformation, with octopamine binding to either both
D100 and S206 (Figure 4C), S210 only (Figure 4D), or sim-
ultaneously binding to S206, S210 and E161 (Figure 4E).
Each of the antagonist and agonist-bound homology
models were simulated for 20 ns in a combination mem-
brane and water environment that approximately repro-
duces the protein’s biological surroundings. The simulationswere stopped every 10 ns and the stability of the ligands
studied. After 20 ns, two of the antagonist-bound active site
conformations and three of the agonist-bound active site
conformations stabilized. The other simulations were con-
tinued for another 10 ns, but no new stable conformations
were observed. The stabilization of the active sites of the five




















Figure 2 Expression levels of AgOAR45A and AgOAR45B.
Quantitative PCR analysis of An. gambiae AgOAR45A (grey) and
AgOAR45B (white) at different life stages, including larvae (L1-L4),
pupae, whole body adult females and males, adult female heads
and thorax/abdomen. Data are expressed as fold change relative to














































Figure 3 Pharmacological characterization of Anopheles gambaie octo
cells. A. Dose response curves of AgOAR45A and AgOAR45B to known oct
(closed boxes), naphazoline (closed triangles), tyramine (closed diamonds),
octopamine receptor antagonists [chlorpromazine (closed circles), cyprohepta
(closed diamonds) of AgOAR45A and in the presence of 1 μM octopamine. D
independent experiments are presented.
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http://www.malariajournal.com/content/13/1/434via calculation of the RMSDs of the MD simulation
trajectories compared to their initial conformations
(see Additional file 7). The ligand and active site for
each conformation were found to have a very stable
interaction for at least ten full nanoseconds (10–20 ns
maximum RMSD fluctuation <1 Å).
Mutagenesis of AgOAR45B
To identify the receptor amino acid residues important
for activity, we performed site-directed mutagenesis ana-
lysis of the residues indicated by the homology model-
ling to be important for binding. A number of studies
have identified important residues vital for GPCR agon-
ist binding activity and have indicated the importance of
an aspartic acid in TM3 (D100) and serine residues in
TM5 (S206 and S210) [10-12] and this has been shown
to be true for α-adrenergic-like octopamine receptors
[46]. MD simulations of AgOAR45B suggested that a glu-
tamic acid (E161) residue in TM4 may also play a role in
ligand recognition. Therefore, AgOAR45B mutants were
constructed changing each of these residues to alanine (A)










































pamine receptors AgOAR45A and AgOAR45B in HEK293-CRE-Luc
opamine receptor agonists [octopamine (OA; closed circles), clonidine
phentolamine (open circles)]. B. Dose response curves of known
dine (closed boxes), metaclopramide (closed triangles), promethazine
ata are expressed as % 1 μM octopamine response. Means ± SD of three
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mutating these residues into their non-charged amino
acids (asparagine (N) and glutamine (Q), respectively) was
further assessed. Mutated forms of AgOAR45B were
generated via site-directed mutagenesis and transiently
expressed into the GloResponse™CRE-luc2P HECK293 re-
porter cell line. Dose response curves for octopamine were
generated for each single and double mutant receptor
(Figure 5). Mutagenesis of either the aspartic acid or the
glutamic acid resulted in loss of AgOAR45B to
responsiveness to octopamine (Figure 5A). Single mutant
analyses revealed that the aspartic acid residue is essential
for octopamine activity as mutagenesis of this residue to
either an alanine or an asparagine completely abolished
octopamine reactivity. The glutamic acid residue, however,
is marginally important for the response (Figure 5A). The
results also indicate that while both serine residues partici-
pate in the octopamine response, S210 is more important
than S206 (Figure 5B).Discovery of four antagonist-binding scaffolds
Two different antagonist conformations of AgOAR45B
were screened against the ZINC library. Of the resulting
1,500 compounds from each of the two conformations,
the top 700 compounds from each were analysed and
separated these compounds into four primary binding-
scaffold groupings which were determined based on the
hydrogen bonding of the D100 residue found in the
active site of the protein with one of four binding sites
in each antagonist: protonated piperazine, protonated
imidazole, protonated -NR2, and a fourth group with
other potential binding scaffolds (see Additional file 8).Discovery of four agonist-binding scaffolds
Similarly, three different conformations were used to
model the agonist conformation. Of the resulting 1,500
compounds from each of the three conformations, the top
250 compounds from each were analysed and separated
these compounds into four binding-scaffold groupings.
These scaffolds were determined based on the hydrogen
bonding of the D100 residue found in the active site of the
protein with one of four binding sites in each agonist:
protonated piperazine, protonated -NR2/-NR3, -NH-R-
NH- (where D100 interacts with both nitrogens), and a
fourth group with other potential binding scaffolds (see
Additional file 9). The other active portion of the com-
pounds appeared to either hydrogen bond with one or the
other of the serine residues in the TM5 region, or
potentially did π stacking with some of the benzene ring-
containing residues in the TM6 region. Both of these resi-
dues have been shown to move in the presence of agonists
[27,28] and were thus both considered. Scaffolds where the
agonist hydrogen bonded only to the E161 residue were
not considered due to E161’s low importance in the
activation of the protein as determined from the
mutagenesis assays (Figure 5).
New potential insecticides
From the 2,150 compounds assessed from the two
antagonist-bound and three agonist-bound conformations,
a total of 70 compounds were chosen and purchased.
These compounds were tested in vitro against AgOAR45B
expressed in the GloResponse™CRE-luc2P HEK293
reporter cell line to determine their efficacy in being an-
tagonists or agonists. Ultimately, 21 antagonists, 17 weak
antagonists, two agonists, and five weak agonists were
identified, while 25 of the 70 compounds were not active
in the reporter assay (see Additional files 10 and 11).
Eight of the compounds identified from the antagonist
conformation ZINC screen (46140767, 46140913, 1279
0591, 15671138, 12434335, 4148879, 24757679, and 4243
7778) inhibited the 1 μM octopamine response of the AgO
AR45B receptor reporter assay by greater than 40%, how-
ever, these compounds decreased the viability of the
HEK293 reporter cells (see Additional files 10 and 11,
superscript c).
Additional chemistries that resulted in a reduction in
receptor stimulation to 1μM octopamine less than two
standard deviations (<80% activity) were chosen for further
characterization. Four compounds (65552607, 32860047,
27417161, and 9274026) exhibited a dose response for at
least two concentrations. Dose–response curves were gen-
erated for 9274026 and 9274026-like compounds (6791
891, 9273955, 15725975, and 9274053) using the AgOA
R45B receptor reporter assay. As the high concentrations
of the 9274026-like compounds were insoluble, IC50 values






Figure 4 Protein conformations resulting from molecular docking of active compounds. The antagonist promethazine can bind to D100 in
two different conformations. Promethazine exhibits H-bonding to D100 of TM3 and does not interact with either of the serines of TM5 (A) and
has potential π -π interactions with either F483 of TM6 or F211 of TM5 (B). The agonist octopamine can potentially H-bond to D100 and S206
(C), S210 (D), or S206, S210, and E161 (E). Octopamine also exhibits potential π -π interactions with either F483 (C) or F484 (D). Note that an
H-bond between octopamine and L97 is also seen in panel E, but was ignored as this is a peptide bond and can thus be made with any amino
acid. (F) Chemical structures of octopamine and promethazine.
Kastner et al. Malaria Journal 2014, 13:434 Page 10 of 14
http://www.malariajournal.com/content/13/1/434indicate that all four of the 9274026-like compounds were
able to inhibit the response of AgOAR45B to 1 μM oc-
topamine as well as the 9274026 compound (11% of the 1
μM octopamine response; IC50 13.2 μM; see Additional
files 10 and 11). Similarly, five compounds similar to
27417161 (12535485, 32843433, 12484738, 00200688, and
02721570) were selected and dose–response curves were
generated. Two of the compounds, 00200688 and 12484738, induced responses similar to 27417161 (~40% inhib-
ition; see Additional files 10 and 11).
Four compounds identified from the agonist-bound
confirmation behaved as weak agonists: 00441586-13%,
48194443-3%, 48345912–8.3%, and 33313914–4.2% of
octopamine response (see Additional files 10 and 11). Five
compounds similar to 48345912 (48354000, 48353672,














































Figure 5 Pharmacological characterization of AgOAR45B
mutants. A. Dose response curves of optopamine E161Q (closed
triangles), E161A (open triangles), D100N (closed squares), D100A
(open squares), D100N/E161Q (closed diamonds), and D100A/E161A
(open diamonds) double mutants. B. Dose response curves of
optopamine S206A (closed boxes), S210A (closed triangles) and
S206A/S210A double mutants (open circles). The same control
wild-type AgOAR45B (closed circles) data is presented in both
A and B. Data are expressed as % 1 μM octopamine response.
Means ± SD of three independent experiments are presented.
Table 2 Binding and larvicide activity of ZINC compounds
ZINC COMPOUND Ki (μM) EC50 (μM) IC50 (μM) Larval bioassay
(% mortality)
OA 7.7 0.017 - nd*
10883478 34.2 - 55.3 74
02643656 14.9 5.6 - nd
40118665 56.7 - 17.6 nd
48353678 2.7 22.0 - nd
48345912 6 - 4.0 nd
*Not detectable.
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agonistic activity higher than to 48345912 (93.4% of
octopamine response). These compounds were further
assessed for antagonistic activity in the presence of 1μM
octopamine and four compounds, 4834512, 48354000,
48353672, and 40118665, were better antagonists than
agonists. Compound 48353678, however, exhibited no
antagonistic activity (see Additional files 10 and 11).
Two additional chemistries identified in the original in
silico screens (10883478 and 02643656) were selected.
One compound, 02643656, exhibited agonist activity
slightly less than 48353678. Compound 10883478 behaved
as an antagonist, inhibiting the response of AgOAR45B to1 μM octopamine by 83%. The 10883478 scaffold was fur-
ther explored by selecting ten compounds (61715350,
58171610, 58007135, 61715380, 7205872, 11207230,
12547680, 39985747, 12794746, and 32322962) from the
ZINC library that were similar to 10883478. Only one
(12547680) had antagonistic activity similar to the parent
compound. None of the compounds exhibited any agonis-
tic activity (see Additional files 10 and 11).
To assess agonist and antagonist binding to AgOAR45B
the best two agonists (48353678 and 02643656) and three
antagonists (10883478, 40118665, and 48345912) were se-
lected and competition binding assays with 3H-Yohimbine
were performed. All the compounds exhibited affinity to
AgOAR45B that was similar to octopamine (i.e. exhibited
Ki values within an order of magnitude of the octopamine
Ki) (Table 2).
To assess insecticidal activity, all 70 compounds in an
Ae aegypti larvicide bioassay were tested.
Only 4 compounds induced any mortality. In the initial
assay (19922690, 12434335, 28695014) induced a small
amount (14-21%) of mortality compared to 0% in the
DMSO alone group at 24 hours and so were not tested fur-
ther. Compound 10883478, however, induced substantial
mortality, killing 70.5 ± 20.5% of the larvae at 24 hours.
Discussion
Octopamine is the most abundant biogenic amine in inver-
tebrates and is virtually absent in vertebrates, making this
pathway an attractive target for insecticide development
with potential low toxicity in vertebrates. Often thought of
as the functional equivalent of vertebrate norepinephrine,
octopamine is an invertebrate neuromodulator, neurohor-
mone and neurotransmitter. The octopaminergic system is
involved in a variety of insect physiological processes,
including locomotion, memory, mating, and egg laying
[47]. Interestingly, cocaine, a natural insecticide, is believed
to potentiate octopaminergic neurotransmission [48]. In
addition, the formamidine pesticides, chlordimeform and
amitraz are thought to act as octopamine agonists [49].
Here, two An. gambiae octopamine receptors, AgOAR45A
and AgOAR45B were functionally characterized. Through
in silico screening approaches one scaffold that holds
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identified.
We identified six full-length OAR/TyrR genes in the
An. gambiae genome. Phylogenetic analysis revealed two
β2-adrenergic like receptors, two TyrR, one OA/Tyr re-
ceptor and a gene that encodes two alternatively spliced
OAR transcripts, AgOAR45A and AgOAR45B. All seven
predicted transcripts shared the characteristic sevem
TM domains characteristic of GPCRs. AgOAR45A and
AgOAR45B are splice variants sharing the first three
exons and differing only with the fourth exon. Both pre-
dicted proteins possess the conserved aspartic acid in
TM3 and two of three conserved serines known to me-
diate binding of GPCRs to biogenic amines [50]. While
identical for the first 246 amino acids, AgOAR45A and
AgOAR45B only share 32% identity (46% similarity) at
the C-terminal end of the protein. These amino acids
encode the third intracellular loop and the C-terminus
of the receptor thought to mediate the interaction
between the GPCR and G-proteins [51,52], invoking the
possibility that the two splice variants couple to different
G-Protein signaling pathways. However, these results
revealed that AgOAR45A and AgOAR45B, both signal
through Ca++ and cAMP, similar to their homologous pro-
teins, DmOamb-B and DmOamb-D, in Drosophila [16,53].
GPCRs generally have three closely grouped serine resi-
dues found in TM5 that are located in the binding site.
AgOAR45B, however, retains only two of these serine resi-
dues. The results demonstrated that D100, S206 and S210
are important in the agonistic function of AgOAR45B to
octopamine, similar to what has been demonstrated for
other GPCR-Ligand combinations [9-11]. It should be
noted however, that while the serine residues do appear to
be important, the function of the protein is not solely
dependent on these residues. Even with both serine resi-
dues replaced, AgOAR45B can still respond to higher con-
centrations of octopamine (Figure 5B). This observation
suggests that another mechanism may be involved in the
activation of this protein. One hypothesis is that the ligand
may also be involved in π-π interactions (i.e. the attractive,
non-covalent interactions that occur between aromatic
rings with some of the aromatic residues) in the TM6 re-
gion (Figure 4). It seems possible that as the TM6 region
moves towards the TM3 region in order to form these
interactions, that the cytoplasmic end of the TM6 region
moves outward. This hypothesis is supported by previous
work in which the cytoplasmic end of TM6 region is shown
to move outward when the protein is activated [27,28].
One interesting scaffold group found to be effective
contained mostly antagonists (48345912, 48354000 and
40118665) and one agonist (48353678). It is likely that
this difference is due primarily to the length of the short
chain to the pyridine group of 48353678, as compared to
the longer chain to the indoline group of 48353672. It ispossible that the shorter chain of 48353678 causes the
active site to be more condensed and be more like the
active conformation, while the longer chain of 48353672
allows the active site to assume a more open and
inactive conformation. Docking of these compounds
shows that both ligands can bind to the same residues in
a similar conformation, yet the longer chain of 48353672
appears to be forcibly constrained and would preferably
be extended, allowing the pocket to open.
Two of the common scaffolds that found docking to
both agonist-bound and antagonist- bound AgOAR45B
conformations, i.e., protonated piperazine and proton-
ated -NR2, were also found in another study performed
with the dopamine D3 receptor [54]. However, none of
the active compounds identified contain protonated
piperazine and only two contain protonated -NR2
(see Additional files 10 and 11). This, along with the pres-
ence of another scaffold that was not reported in the
dopamine D3 receptor study, i.e., protonated imidazole
(which 10883478 contains), indicates that there may be
specificity for AgOAR45B to certain compound types.
Four of the compounds exhibited activity against
mosquito larvae in an initial assay. Interestingly, these
compounds were among the best antagonists and exhib-
ited between 14 and 70.5% in a mosquito larval bioassay.
Three (10883478, 12434335 and 28695014) of the four
were imidazole derivatives with different carbon and
nitrogen substitution patterns. Interestingly, a compound
from the same scaffold as 10883478 that also exhibited
potent antagonist activity was not active in the larvicide
bioassay. Possibly, the ortho methyl substitution of
10883478 makes this compound less susceptible to
metabolism.
Conclusions
Here, two An. gambiae OARs were functionally character-
ized and a computational approach coupled with experi-
mental methods was utilized to discover possible lead
compounds for the development of novel insecticides. We
identified two AgOAR45B agonists and twenty-one antag-
onists, with one antagonist exhibiting substantial larvicide
activity in a mosquito bioassay. However, we were unable
to directly attribute OAR antagonism to the killing activity
because of potential off target effects at the high concen-
trations utilized. Further studies on all the compounds to
enhance potency, increase stability, and assess possible off
target effects are needed. In addition, refinement of the
computational models utilized for virtually screening will
increase the possibility of identifying additional compounds
for development. Running longer conventional MD
simulations for ensuring optimal states is computationally
impractical; however, accelerated molecular dynamics
(aMD) will allow simulations on the millisecond timescale
in only hundreds of nanoseconds [48]. In addition, a
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more accurate model of the protein for the in silico
discovery of lead compounds.
Additional files
Additional file 1: Primer sequences for mutagenesis of AgOAR45B.
Additional file 2: Diagram of the basic computational-experimental
workflow.
Additional file 3: Alignment of AgOAR45B (AGAP000045B) with
human b2-adrenergic receptor (NP_000015). Black boxes indicate
active site residues. AgOAR45B exhibits a 67% sequence active site
identity (73% similarity) to the β2-adrenergic receptor active site.
Additional file 4: Genomic organization of AgOAR45A and
AgOAR45B. AGAP000045 region downloaded from VectorBase. Maroon
boxes indicate protein-coding regions. B) Protein alignment of the two
proteins performed using Geneious software. Red boxes indicate
transmembrane regions. Note low identity after position 250. C)
Hydropathy Plot for AGAP000045B.
Additional file 5: AgOAR45A and AgOAR45B Gαq signaling. Dose
response curves of AgOAR45A (circles) and AgOAR45B (squares) to
known different concentrations of octopamine. Data are expressed as the
change in fluorescence intensity (Fmax-Fmin) divided by the background
fluorescence intensity (Fmin) % 1 μM octopamine response. Means ± SD
of three independent experiments are presented.
Additional file 6: AgOAR45B homology models obtained from
I-TASSER. Blue indicates the inactive conformation while orange indicates
the active conformation. Promethazine, shown in green, indicates the active
site. Both sides of the proteins are presented, with (A) showing TM 1–5 and
(B) showing TM 5–7, 2, and 1. Total Protein RMSD: 10 Å. TM-region RMSD:
2 Å.
Additional file 7: RMSDs of MD simulation trajectories compared to
their respective initial conformations. (A) RMSD MD simulation yielding
antagonist-bound conformation presented in Figure 4A, max flux = 0.82Å.
(B) RMSD MD simulation yielding antagonist-bound conformation
presented in Figure 4B, max flux = 0.86 Å. (C) RMSD MD simulation
yielding agonist-bound conformation presented in Figure 4C, max
flux = 0.38Å. (D) RMSD MD simulation yielding agonist-bound conformation
presented in Figure 4D, max flux = 0.47Å. (E) RMSD MD simulation yielding
agonist-bound conformation presented in Figure 4E, max flux = 0.72 Å.
Max flux values reported are the largest RMSD differences in the 10–20 ns
simulation trajectories for the respective runs.
Additional file 8: Scaffolds obtained from antagonist-bound
screens. The most commonly observed interactions with D100 in the
virtual screen were (A) protonated piperazine, (B) protonated imidazole
and, (C) protonated -NR2. Figure (D) shows one of the other potential
interactions that were observed.
Additional file 9: Scaffolds obtained from agonist-bound screens.
The most commonly seen interactions with D100 in the virtual screen
were (A) protonated piperazine, (B) protonated -NR2/-NR3 and, (C) -NH-R-
NH- (where D100 interacts with both nitrogens). Figure (D) shows one of
the other potential interactions that were observed.
Additional file 10: Activity of Zinc compounds tested in vitro.
Additional file 11: Zinc chemistries purchased and tested in the
AgOAR45B reporter assay.
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